Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc. (NASDAQ: ACOG), highlighting the company's progress with its Alzheimer's treatment ZUNVEYL. According to the update, Alpha Cognition exited fiscal year 2025 with increasingly durable traction in long-term care (LTC) markets. Fourth-quarter net product revenue reached $2.5 million, contributing to total fiscal year 2025 revenue of $10.2 million, which included $6.8 million from ZUNVEYL sales.
Demand indicators continued to inflect positively. Bottles dispensed rose 62% quarter-over-quarter to 4,941, with December alone reaching a record 1,859 bottles. Repeat ordering remained strong, supporting management's view that ZUNVEYL is moving beyond early trial use and becoming more embedded in facility treatment protocols. The number of ordering homes reached 729, with an 82% repeat order rate. Additionally, 865 prescribers were recorded, with 69% being repeat writers, further indicating protocol adoption in LTC settings.
Alpha Cognition is well-funded to continue scaling commercialization. The company ended fiscal year 2025 with $66.0 million in cash, providing a runway into 2027. Management expects continued sequential sales growth in 2026. The full announcement, including downloadable images and bios, can be viewed here.
Key takeaways from the update include: ZUNVEYL adoption is becoming durable with 4Q25 sales of $2.5 million and a 62% sequential increase in bottles dispensed to 4,941; LTC traction is strengthening with repeat behavior evidenced by 729 ordering homes, 82% repeat orders, and 69% repeat prescribers; and ACOG is funded to keep scaling commercialization with $66.0 million cash runway into 2027.
Stonegate Capital Partners is a capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services. Its affiliate, Stonegate Capital Markets (member FINRA), offers investment banking services. For more information, contact Stonegate Capital Partners at (214) 987-4121 or visit their website.
